{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:16:51Z","timestamp":1783426611544,"version":"3.54.6"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.msard.2026.107331","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T14:39:47Z","timestamp":1782052787000},"page":"107331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world impact of national policy on high-efficacy therapy use in multiple sclerosis: A Brazilian big data analysis"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0827-7281","authenticated-orcid":false,"given":"Alexandre Coelho","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Martins","family":"Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriely Rangel","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo Betti","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Hernandes","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doralina Guimaraes Brum","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edson Amaro","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia Almeida","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107331_bib0001","series-title":"Resolu\u00e7\u00e3o Normativa RN No. 465, De 24 De Fevereiro De 2021 [Normative Resolution No. 465, February 24, 2021]","year":"2021"},{"key":"10.1016\/j.msard.2026.107331_bib0002","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3389\/fphar.2019.00984","article-title":"Administrative data linkage in Brazil: potentials for health technology assessment","volume":"10","author":"Ali","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.msard.2026.107331_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210251","article-title":"Inequities in the use of disease-modifying therapy among adults living with multiple sclerosis in urban and rural areas in Alberta, Canada","volume":"104","author":"Balcom","year":"2025","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2026.107331_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2026.1738815","article-title":"Predictors of initiating high-efficacy vs. platform therapies as first-line disease-modifying treatment in multiple sclerosis","volume":"17","author":"Bin Aziz","year":"2026","journal-title":"Front. Neurol."},{"issue":"6578","key":"10.1016\/j.msard.2026.107331_bib0005","first-page":"296","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science (1979)"},{"issue":"Suppl 2","key":"10.1016\/j.msard.2026.107331_bib0006","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1007\/s10072-008-0954-x","article-title":"Induction vs escalating therapy in multiple sclerosis: practical implications","volume":"29","author":"Comi","year":"2008","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.msard.2026.107331_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12939-023-01828-3","article-title":"Persistent inequalities in health care services utilisation in Brazil (1998-2019)","volume":"22","author":"Coube","year":"2023","journal-title":"Int. J. Equity. Health"},{"issue":"6","key":"10.1016\/j.msard.2026.107331_bib0008","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.msard.2015.08.004","article-title":"Papais Alvarenga RM. Prevalence of multiple sclerosis in Brazil: a systematic review","volume":"4","author":"da Gama Pereira","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107331_bib0009","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2026.107331_bib0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40263-013-0065-y","article-title":"Induction therapy for patients with multiple sclerosis: why? When? How?","volume":"27","author":"Edan","year":"2013","journal-title":"CNS. Drugs"},{"issue":"11","key":"10.1016\/j.msard.2026.107331_bib0011","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1093\/brain\/awaa306","article-title":"Aggressive multiple sclerosis: a matter of measurement and timing","volume":"143","author":"Ellenberger","year":"2020","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2026.107331_bib0012","first-page":"74","article-title":"Expenditure, utilization, and cost of specialty drugs for multiple sclerosis in the US Medicaid population, 2008-2018","volume":"13","author":"Elsisi","year":"2020","journal-title":"Am. Health Drug Benefits"},{"issue":"5","key":"10.1016\/j.msard.2026.107331_bib0013","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00228-018-2429-1","article-title":"The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations","volume":"74","author":"Eriksson","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.msard.2026.107331_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12913-018-2851-1","article-title":"Resource allocations and disparities in the Brazilian health care system: insights from organ transplantation services","volume":"18","author":"G\u00f3mez","year":"2018","journal-title":"BMC. Health Serv. Res."},{"key":"10.1016\/j.msard.2026.107331_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106466","article-title":"Socioeconomic impact of initial high vs. moderate efficacy disease-modifying therapy in multiple sclerosis: effects on labor market affiliation","volume":"99","author":"Holm","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10422","key":"10.1016\/j.msard.2026.107331_bib0016","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2026.107331_bib0017","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp.2011.240432","article-title":"Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis","volume":"82","author":"Simpson","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2026.107331_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-26090-5","article-title":"Systematic analysis of healthcare big data analytics for efficient care and disease diagnosing","volume":"12","author":"Khan","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107331_bib0018","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44197-025-00353-6","article-title":"Epidemiology of Multiple sclerosis: global, regional, national and sub-national-level estimates and future projections","volume":"15","author":"Khan","year":"2025","journal-title":"J. Epidemiol. Glob. Health"},{"key":"10.1016\/j.msard.2026.107331_bib0020","doi-asserted-by":"crossref","DOI":"10.1590\/1677-5449.20210186","article-title":"Temporal trends in vena cava filter implantation in public health system inpatients: an 11-year analysis of the largest city in Brazil","volume":"21","author":"Leiderman","year":"2022","journal-title":"J. Vasc. Bras."},{"key":"10.1016\/j.msard.2026.107331_bib0021","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas \u2013 Esclerose M\u00faltipla. Portaria SAS\/MS n\u00b0 493, De 23 De Setembro De 2010","year":"2010"},{"key":"10.1016\/j.msard.2026.107331_bib0022","series-title":"Portaria n\u00b0 1.554, De 30 De Julho De 2013: Disp\u00f5e Sobre As Regras De Financiamento e Execu\u00e7\u00e3o Do Componente Especializado Da Assist\u00eancia Farmac\u00eautica No \u00e2mbito do Sistema \u00danico De Sa\u00fade (SUS)","year":"2013"},{"key":"10.1016\/j.msard.2026.107331_bib0023","series-title":"Secretaria De Aten\u00e7\u00e3o Especializada \u00e0 Sa\u00fade; Secretaria de Ci\u00eancia, Tecnologia","article-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas da Esclerose M\u00faltipla. Portaria Conjunta n\u00b0 1, de 7 de janeiro de 2022","year":"2022"},{"key":"10.1016\/j.msard.2026.107331_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241237857","article-title":"Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis - real-world evidence from Germany","volume":"17","author":"Papukchieva","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107331_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104581","article-title":"Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: a systematic review and meta-analysis","volume":"71","author":"Pipek","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107331_bib0026","article-title":"Multiple sclerosis: emerging epidemiological trends and redefining the clinical course","volume":"44","author":"Portaccio","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.msard.2026.107331_bib0027","article-title":"COVID-19 and multiple sclerosis: challenges and lessons for patient care","volume":"44","author":"Prosperini","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"10.1016\/j.msard.2026.107331_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105380","article-title":"Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: a time and motion study","volume":"82","author":"Rog","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107331_bib0029","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fneur.2018.00781","article-title":"Therapeutic inertia in Multiple sclerosis care: a study of Canadian neurologists","volume":"9","author":"Saposnik","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107331_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.msard.2019.05.029","article-title":"Emotional expressions associated with therapeutic inertia in multiple sclerosis care","volume":"34","author":"Saposnik","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2026.107331_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/jnnp-2022-329987","article-title":"Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network","volume":"94","author":"Signori","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2026.107331_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.693017","article-title":"Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry","volume":"12","author":"Simonsen","year":"2021","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107331_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200021","article-title":"Updated results of the COVID-19 in MS Global Data Sharing Initiative: anti-CD20 and other risk factors associated with COVID-19 severity","volume":"9","author":"Simpson-Yap","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2026.107331_bib0034","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1007\/s00415-024-12305-4","article-title":"Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption","volume":"271","author":"Singer","year":"2024","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2026.107331_bib0035","doi-asserted-by":"crossref","first-page":"e624","DOI":"10.1212\/WNL.0000000000207481","article-title":"Global Barriers to the diagnosis of Multiple Sclerosis: data from the Multiple Sclerosis International Federation Atlas of MS, third edition","volume":"101","author":"Solomon","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107331_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102512","article-title":"Impact of the COVID-19 pandemic on the health care of >1000 people living with multiple sclerosis: a cross-sectional study","volume":"46","author":"Vogel","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2026.107331_bib0037","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.msard.2026.107331_bib0038","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/CON.0000000000001136","article-title":"Epidemiology and pathophysiology of multiple sclerosis","volume":"28","author":"Ward","year":"2022","journal-title":"Continuum (Minneap. Minn)"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826003676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:35:32Z","timestamp":1783424132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826003676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"alternative-id":["S2211034826003676"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107331","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact of national policy on high-efficacy therapy use in multiple sclerosis: A Brazilian big data analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107331"}}